Aarti Pharmalabs Surges on Strong Q1 FY27 Performance and Capacity Expansion

Consolidated Revenue: ₹535.8 crore
Consolidated PAT: ₹76.1 crore

Reader Takeaway: Robust Q1 growth driven by capacity expansion and CDMO pipeline, balanced by raw material cost concerns.

What just happened

Aarti Pharmalabs Ltd reported a strong financial performance for the first quarter of FY27 (ending June 2026). Consolidated revenue surged by 39% year-on-year to ₹535.8 crore, while Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) increased to ₹132.6 crore. Profit After Tax (PAT) saw a substantial jump of 65% to ₹76.1 crore. The company also commissioned its Tarapur Unit 5, adding 3,600 tonnes per annum (TPA) to its Xanthine Derivatives capacity, bringing the total to over 9,600 MTPA. Production at Unit 4's Steroid API Block also saw a one-third capacity increase after a debottlenecking shutdown.

Why this matters

These results demonstrate Aarti Pharmalabs' ability to grow its top and bottom lines significantly, driven by both increased production and expanding market reach in its Contract Development and Manufacturing Organisation (CDMO) segment. The capacity additions are crucial for meeting future demand and supporting the company's growth targets. The positive outlook and explicit guidance provide investors with a clear vision for the company's strategic direction.

The backstory

Aarti Pharmalabs has been focused on strategic reinvestment and capacity building. The company previously completed capacity additions and is now embarking on further brownfield expansion, such as the Atali Block 2 project, specifically tailored for CDMO/CMO requirements, slated for commercialization by H2 FY28. This indicates a sustained focus on enhancing its manufacturing capabilities.

What changes now

The company has set a clear growth trajectory, guiding for a 15-18% compound annual growth rate (CAGR) in both revenue and EBITDA over the next three to four years. The FY27 capital expenditure (Capex) is expected to remain at levels similar to FY26's approximately ₹400 crore. The successful integration of the new capacities and the progress on the Atali project will be key to achieving these targets.

Risks to watch

Management has highlighted that raw material prices remain elevated due to geopolitical factors. While there are early signs of easing in the supply chain, this situation warrants close monitoring. The company needs to effectively manage these cost pressures to maintain its healthy EBITDA margins, which stood at approximately 24.75% in Q1 FY27.

Peer comparison

Companies in the pharmaceutical and specialty chemicals sector, such as Divi's Laboratories and Laurus Labs, also focus on capacity expansion and CDMO services. Aarti Pharmalabs' specific focus on Xanthine Derivatives and Steroid APIs, coupled with its strong CDMO pipeline, positions it within a competitive but growing market segment.

Context metrics (time-bound)

In Q1 FY27, Aarti Pharmalabs achieved ₹535.8 crore in revenue with an EBITDA margin of 24.75% and a PAT margin of 14.20%. The company plans a ₹149 crore capex for Atali Block 2, expected by H2 FY28. FY26 capex was around ₹400 crore, with similar levels anticipated for FY27.

What to track next

Investors will be watching the successful ramp-up of the new Tarapur Unit 5 capacity and the progress of the Atali Block 2 brownfield capex. Monitoring raw material price trends and the company's ability to pass on costs or improve efficiency will be crucial for sustained margin performance.